dr. W.M. Smit

Functie: Internist-hematoloog
Bereikbaarheid: Secretariaat: (053) 487 24 40

Nevenfuncties

  • 2005-heden: Opleider Inwendige Geneeskunde MST
  • 1999-2009: Lid Medisch Ethische Toetsingscommissie MST
  • 1999-2010: Lid Oncologiecommissie MST
  • 2003-2011: Lid Commissie Beoordeling Oncologische Medicatie (CieBOM)
  • 2008-2017: Voorzitter Centrale Opleidings Commissie MST
  • 2003-heden: Consulent Hematologie IKNL
  • 2006-heden: Lid adviesraad Continuüm Oncologie
  • 2010-heden: Lid Concilium Interne Geneeskunde
  • 2015-heden: Secretaris Concilium Interne Geneeskunde
  • 2011-heden: Lid Plenaire Visitatie Commissie Interne Geneeskunde
  • 2015-heden: Lid Commissie Behoefteraming en Capaciteiteitsplanning Interne Geneeskunde
  • 2017-heden: Affiliatie coördinator co-assistenten

Opleiding

  • 1976-1983: Studie geneeskunde, Vrije Universiteit, Amsterdam
  • 1987-1992: Interne Geneeskunde, Onze Lieve Vrouwe Gasthuis, Amsterdam
    (opleider dr. J. Silberbusch)
  • 1992-1996: Aantekening hematologie, Leids Universitair Medisch Centrum
  • 1996-1997: Internist afdeling Medische Oncologie, Nederlands Kanker Instituut, Amsterdam
  • 1997-heden: Internist-hematoloog Medisch Spectrum Twente
  • 19 november 1999: Proefschrift “Allogenic cytotoxic T lymphocyte responses against chronic myeloid leukaemia” (promotor Prof dr. J.H.F. Falkenburg en Prof dr. R. Willemze)

Onderzoeken

Onderzoeksprojecten

  • Subsidie van de Nederlandse Kankerbestrijding voor een postdoc en een analiste voor het project Allogeneic Cellular Immunotherapy of Chronic Lymphocytic Leukemia
    Onderzoekers: prof.dr. J.H.F. Falkenburg, dr. W.M. Smit en prof.dr. R. Willemze

Lid promotiecommissie

  • C.F. van Uden-Kraan. Online Peer Support for Somatic Diseases. 21-11-2008. Universiteit Twente
    (als referent)
  • J.M. Mekenkamp. Studies in Colorectal Cancer metastases: implications for clinical practice.16-4-2013. Radboud Universiteit. Nijmegen.

Publicaties

W.M. Smit, H.M. Oudemans-van Straaten and D.F. Zandstra. Fulminant falciparum malaria. Intensive Care Medicine 1990;16: 517-519.

W.M. Smit, H.M. Oudemans-van Straaten and D.F. Zandstra. Malaria tropica. Intensive Care Review 1991; 6: 152-155 .

W.M. Smit, J.I. van der Spoel, J. Veenstra. Rhabdomyolyse na gebruik van heroïne en alcohol.

Intensive Care Review  1992: 7: 125-129.

G.H. Ho, W.M. Smit, E.J. Haanraadts, J.J.A.M. ten Velden en H.F.W. Hoitsma. Leiomyosarcoom van de dunne darm: een zeldzame oorzaak van gastro-intestinaal bloedverlies. Nederlands Tijdschrift voor Geneeskunde 1993: 137:1400-1403.

W.M. Smit, M.A.J. Wagemans, G.J. v.d.Horn and J.S. Surachno. Acute retinal necrosis in a renal allograft recipient (An unusual manifestation of cytomegalovi­rus infection). Transplantation 1993; 55: 219-221.

J.H.F. Falkenburg, L.M. Faber, M. van den Elshout, S.A.P. van Luxemburg-Heijs, A. Hooftman-Den Otter, W.M. Smit, P.J. Voogt and R.Willemze. Generation of donor-derived antileukemic cytotoxic T-lymfocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation. Journal of Immunotherapy  1993;14: 305-309.

Veenstra, W.M. Smit, R.T. Krediet and L. Arisz. Relationship between elevated creatine phosphokinase and the clinical spectrum of rhabdomyo­lysis. Nephrology Dialysis Transplantation 1994; 9: 637-641.

C.A.M. van Bergen, W.M. Smit, D.A. van Sluijters, M. Rijnbeek, R. Willemze and J.H.F. Falkenburg.

Interleukin-10, Interleukin-12 and Tumor Necrosis Factor-a differentially influence the proliferation of human CD8+ and CD4+ T cell clones. Annals of Hematology 1996; 72: 245-252.

 

W.M. Smit, M. Rijnbeek, C.A.M. van Bergen, R.A. de Paus, H.A.W. Vervenne, M. van de Keur, R. Willemze and J.H.F. Falkenburg. Generation of dendritic cells expressing bcr/abl from CD34 positive chronic myeloid leukemia precursor cells. Human Immunology 1997; 53: 216-223.

J.H.F. Falkenburg, W.M. Smit, R. Willemze. Cytotoxic T lymphocytes responses against acute and chronic myeloid leukemia. Immunological Reviews 1997; 157: 223-230.

W.M. Smit, M. Rijnbeek, C.A.M. van Bergen, R. Willemze, J.H.H. Falkenburg. Generation of leukemia reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay. Bone Marrow Transplantation 1998; 21: 553-560

W.M. Smit, M. Rijnbeek, C.A.M. van Bergen, W.E. Fibbe, R. Willemze,  J.H.F. Falkenburg.

T cells recognizing leukemic CD34+ progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 1998; 95: 10152-10157.

J.H.F. Falkenburg, A.R. Wafelman, P. Joosten, W.M. Smit, C.A.M. van Bergen, R. Bongaerts, E. Lurvink, M. van der Hoorn, P. Kluck, J.E. Landegent, J. C. Kluin-Nelemans, W.E. Fibbe, R. Willemze. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999; 94: 1201-1208

  1. H. Meerwaldt, N. v. Bentem, J. J. Kolkman, P. Noach, G. v. Olffen, W. M. Smit. Combined intraluminal and external irradiation of oesophageal cancer, a curative option? European Journal of Gastroenterology & Hepatology 1999; 11(12). 148

M.E. Gore, R.J. Atkinson, H. Thomas, H. Cure, D. Rischin, P. Beale, P. Bougnoux, L. Dirix, W.M. Smit. Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval. Eur J Cancer. 2002; 38:S7-12.

M.E. Gore, R.J. Atkinson, H. Thomas, H. Cure, D. Rischin, P. Beale, P. Bougnoux, L. Dirix, W.M. Smit. A phase II trial of ZD0473 in platinum-pretreated ovarian cancer. Eur J Cancer. 2002; 38: 2416-20.

E.F. Posthuma, E.W. Marijt, R.M. Barge, R.A. van Soest, I.O. Baas, C.W. Starrenburg, S.L. van Zelderen-Bhola, W.E. Fibbe, W.M. Smit, R. Willemze, J.H. Falkenburg. Alpha-Interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Biol Blood Marrow Transplant. 2004;10:204-12.

  1. Hoogendoorn, J. Olde Wolbers, W.M. Smit, M.R. Schaafsma, R.M.Y. Barge, R. Willemze, J.H.F. Falkenburg. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy. Leukemia 2004; 18: 1278-1287

K.L. Wu, H.H. Helgason, B. van der Holt, P.W. Weijermans, H.M. Lokhorst, W.M. Smit, P. Sonneveld. Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myelom: response of soft-tissue plasmacytomas. Leukemia 2005; 19: 143-145.

 

M.H. Wobbes, M.R. de Groot, J.T.J. Brons, W.M. Smit. Zwangerschap en chemotherapie; een schijnbare tegenstelling. Nederlands Tijdschrift voor Geneeskunde 2004; 148: 349-352.

 

F.G.A. Jansman, A.J.A. Jansen, J.L.L.M. Coenen, J.C. de Graaf, W.M.Smit, J.R.B.J. Brouwers. Klinische relevante interacties van 5-fluorouracil/leucovorin met andere geneesmiddelen bij patienten met colorectale kanker. Pharmaceutisch Weekblad 2004; 139(42): 1392-1396.

 

H.R. Franke, W.M. Smit, I. Vermes. Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin’s disease undergoing chemotherapy. Gynecological Endocrinology 2005; 20(5):274-278.

 

F.G.A. Jansman, F.S.F. Idzinga, W.M. Smit, J.C. de Graaf, J.L.L.M. Coenen, D.Th. Sleijfer, J.R.B.J. Brouwers. Clinically significant drug-interactions with irinothecan and with oxaliplatin in patients with colorectal cancer.  Clinical Therapeutics 2005; 27(3): 327-335

 

M. Hoogendoorn, J. Olde Wolbers, W.M. Smit, M.R. Schaafsma, I. Jedema, R.M.Y. Barge, R. Willemze, J.H.F. Falkenburg.  Primary allogeneic T-cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation. Clinical Cancer Research 2005; 11(14); 5310-5318.

 

R.Komdeur, B.S. Hylkema, J. Slomp, W.M. Smit. Transfusie gerelateerde acute longbeschadiging: de adembenemende zijde van bloed. Nederlands Tijdschrift voor Hematologie 2005; 2(5)165-173.

 

F.G.A. Jansman, A.J.A. Jansen, J.L.L.M. Coenen, J.C. de Graaf, W.M. Smit, D.Th. Sleijfer, J.R.B.J. Brouwers. Clinically significant drug-interactions with 5-fluorouracil/leucovorin in patients with colorectal cancer.  American Journal of Health-System Pharmacy 2005; 62(17): 1788-1793.

 

E.J.M. Siemerink, W.M. Smit. Hyperviscositeitsyndroom bij plasmacel dyscrasieen. Nederlands Tijdschrift voor Hematologie. 2006; 3(1): 24-28.

 

S. Rodenhuis, M. Bontenbal, L.V.A.M. Beex, W.M. Smit, M.A. Nooij, E. E. Voest, M, E. van der Wall, P. Hupperets, H. van Tinteren, J.L. Peterse, M.J. van de Vijver,  E.G.E. de Vries, for the Netherlands Working Party on Autologous Transplantation in Solid Tumors.  Efficacy of High-Dose Alkylating Chemotherapy in HER2/neu-negative Breast Cancer. Annals of Oncology 2006; 17(4): 588-596.

 

S. Corporaal, W.M. Smit, M.G.V.M. Russel, J. van der Palen, H.Boot, M.C.J.C. Legdeur. Capecitabine, epirubicin and cisplatin in treatment of esophago-gastric adenocarcinoma. Neth J Med 2006; 64(5) 141-146.

 

T.M. Bosch, A.D.R. Huitema, V.D. Doodeman, R. Jansen, P.O. Witteveen, W.M. Smit, R.L. Jansen, C.M. van Herpen, M. Soesan, J.H. Beijnen, J.H.M. Schellens. Pharmacogenetic screening of CYP3A and MDR1 in relation to population pharmacokinetics of docetaxel. Clinical Cancer Research 2006; (12) 5786-5793.

 

J. Hannemann, P. Kristel, H. van Tinteren, M. Bontebal, Q.G.C.M. van Hoensel, W.M. Smit, M.A. Nooij, E.E. Voest, E. van der Wall, P. Hupperets, E.G.E. de Wall, S. Rodenhuis, M. van de Vijver. Molecular subtypes of breast cancer and amplification of Topoisomerase IIa: predictive role in dose intense adjuvant chemotherapy. British Journal of Cancer 2006 (9) 1334-1341.

 

B.I. Hiddinga, J.Slomp, W.M. Smit. Arseentrioxide voor het bereiken van een complete remissie na recidief acute promyelocyten leukemie.  Nederlands Tijdschrift voor Hematologie 2006; 3 (6): 230-235

 

W. Deenik, B. van der Holt, G.E. Verhoef, A.V. Schattenberg, L.F. Verdonck, S.M. Daenen, P. Zachee, P.H. Westveer, W.M. Smit, S. Wittebol, H.C. Schouten, B. Lowenberg, G.J. Ossenkoppele, J.J. Cornelissen. High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study. Annals of Hematology 2007; (86) 117-125.

 

E. van Dalen, R. Komdeur, T. van Voorthuizen, W.M. Smit. Filgrastim geïnduceerd syndroom van Sweet bij een patient met acute promyelocytenleukemie. Nederlands Tijdschrift voor Hematologie 2007: 4 (7) 274-276.

 

C. Buijs, S. Rodenhuis, M. Bontebal, L.V.A.M. Beex, E. van der Wall, W.M. Smit, M.A. Nooij, E. Voest, P. Hupperets, E.M. ten Vergert, H. van Tinteren, P.H.B. Willemse, M.J.E. Mourits, N.K. Aaronson, W.J. Post, E.G.E. de Vries. Long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health related quality of life: a prospective study. Journal of Clinical Oncology 2007; 25: 5403-5409.

 

C.F. Kraan, C.H.C. Drossaert, E. Taal, C.E.I. Lebrun, K.W. Drossaers-Bakker, W.M. Smit, E.R. Seydel, M.A.F.J. van de Laar. Coping with somatic illnesses in online support groups: do the feared disadvantages actually occur. Computers in Human Behavior 2008; 24: 309-324.

 

W. Deenik, B van der Holt, G. E.G. Verhoef, W. M. Smit, M. J. Kersten, J.C. Kluin-Nelemans, L. F. Verdonck, A. Ferrant, A.V.M.B. Schattenberg, J.J.W.M. Janssen, P. Sonneveld, M. van Marwijk Kooy, S. Wittebol, R. Willemze, P. W. Wijermans, P.H.M. Westveer, H. B. Beverloo, P. Valk, B. Löwenberg, G.J. Ossenkoppele, J.J. Cornelissen. Dose finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood 2008; 211: 2581-2588.

 

P. Nieboer, E.G. de Vries, N.H. Mulder, S. Rodenhuis, M. Bontebal, E. van der Wall, QG van Hoensel, W.M. Smit,  P. Hupperets, E.E. Voest, M.A. Nooij, H.M. Boezen, W.T.A. van der Graaf. Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients. Bone marrow Transplantation 2008; 42(7): 475-481.

 

C.F. van Uden-Kraan, C.H.C. Drossaert, E. Taal, W.M. Smit, H.J. Bernelot Moens, S. Siesling, E.R. Seydel, M.A.F.J. van de Laar. Health-related internet use by patients with somatic diseases: frequency of use and characteristics of uses. Informatics for Health and Social Care 2009; 34: 18-29.

 

W.W. ten Bokkel Huinink, J. Sufliarsky, W.M. Smit, D.Dizon, S. Spinak, A. Oza, H.W. Hirte. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or perioneal cancer: a phase I, open-label, dose-escalating study. Journal of Clinical Oncology 2009; 27: 3097-3103.

 

S.L.W. Koolen, A.D.R. Huitema, R.S. Jansen, T. van Voorthuizen, J.H. Beijnen, W.M. Smit, J.H.M. Schellens. Pharmacogebetics of gemcitabine and metabolites in a patient with both-sided nefrectomy: a case report and a review of the literature. The Oncologist 2009; 14: 944-948.

 

M. van de Ven, V. Silderhuis, R.M.L. Brouwer, M.C.J.C. Legdeur, W.M. Smit. Patienten met een hematolgische maligniteit op de intensive care. Nederlands Tijdschrift voor Geneeskunde 2009; 153: 2247-2251.

 

W. Deenik, J.J.W.M. Janssen, B. van der Holt, G.E.G. Verhoef, W.M. Smit, M.J. Kersten, J.C. Kluin-Nelemans, L.F. Verdonck, A. Ferrant, A.V.M.B. Schattenberg, I.T. Chu, C.S. Goudswaard, P. Sonneveld, M. van Marwijk Kooy, S. Wittebol, R. Willemze, P.W. Wijermans, S. Verelst,  H.B. Beverloo, B. Löwenberg, P.J.M. Valk,  G. J. Ossenkoppele, J.J. Cornelissen. Efficacy of escalated imatinib and cytarabine in newly diagnosed patients with chronic myeloid leukemia. Result of the Dutch Belgian HOVON-51 study. Haematologica 2010; 95: 914-921.

 

C.F. van Uden-Kraan, C.H.C. Drossaert, E. Taal, C.B. Peek, W.M. Smit, E.R. Seydel, M.A.F.J. van de Laar. Experiences and attitudes of Dutch rheumatologists and oncologists with regard to their patients’ health-related Internet use. Clinical Rheumatology 2010; 11: 1229-1236.

 

J.R. Kroep, S.C. Linn, E. Boven, H. Bloemendal, J. Baas, I. Mandjes, J. van den Bosch, W.M. Smit, H. de Graaf, C.P. Schroder, G.J. Vermeulen, W.C.J. Hop, J.W.R. Nortier. Lapatinib for advanced breast cancer progressive on trastuzemab, the Dutch experience. Netherlands Journal of Medicine 2010; 68: 371-376.

 

P.Hamberg, M.M.E.M. Bos, H.J.J. Braun, J.M.L. Stouthard, G.A. van Deijk, F.L.G. Erdkamp, I.N. van der Stelt-Frissen, M. Bontebal, G.J.M. Creemers, J.E.A. Portielje, J.F.M. Pruijt, O.J.L. Loosveld, W.M. Smit, E.W. Muller, P.I.M. Schmitz, J.G.M. Klijn, C. Seynave. Randomized phase II study comparing efficacy and safety of combination therapy trastuzemab/docetaxel versus sequential therapy trastuzemab followed by docetaxel at progression as first line chemotherapy for Her2-overexpressing metastatic breast cancer. Clinical Breast Cancer 2011; 11:103-112.

 

C.P. Schroder, L. de Munck, P.H. Willemse, W.M. Smit, G.J. Creemers, H. De Graaf, J.M. Stouthart, G. van Deijk, Z. Erjavec, A. van Bochove, W. Vader, A.M. Westermann. Tolerability of weekly versus three-weekly docetaxel: a randomized, multicenter phase III study in metastatic breast cancer patients. Ann Oncology 2011; 47: 1355-1362.

 

G.J. Ossenkoppele, J.J.W.M. Janssen, E.F.M. Posthuma, J.H.F. Falkenburg, B.J. Biemond, G.M.J. Bos, E.J. Petersen, A.V.M.B. Schattenberg, W.M. Smit, G.E.G. Verhoef, E. Vellenga, J.J. Cornelissen. Aanbevelingen voor de behandeling van chronische myeloide leukemie 2011. Nederlands tijdschrift voor Hematologie 2011; 8 : 237-247.

C.F. van Uden-Kraan, C.H.C. Drossaert, E. Taal, W.M. Smit, H.J. Bernelot Moens, M.A.F.J. van de Laar. Determinants of engagement in face-to-face and online patient support groups. J Med Internet Res  2011; 13(4): e106

A.K.L. Reynders, W.M. Smit, M. Schaapveld, L. de Munck, K. Hoekman, F.L.G. Erdkamp, R.L. Lalisang, H. de Graaf, A.N.M. Wymenga, M. Polee, P.H.B. Willemse. A randomiized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian cancer, fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Ann Oncol  2012; 23(11): 2896-2902.

 

C.L.E. Hazenberg, G.J. Ossenkoppelle, W.M. Smit. Raynaud like phenomen as a side effect of nilotinib. Br. J. Haematol. 2012; 158(4): 431.

 

W.M. Smit, J. Sufliarsky, T.L. Werner, D.S. Dixon, M. Wagnerova, H.W. Hirte, N.M. Spirtos, A. Oza, L. Dirix, M. El-Hashimy, S. Acharyya, E.Y. Tan, D. Weber, J.H.M. Schellens. A phase II study of Patupilone in patients with platinum-resistant or -refractory ovarian cancer. Clinical Ovarian Cancer 2012; 5(2): 53-59

 

N. Thielen, B. van der Holt, G. Verhoef, R. Ammerlaan, P. Sonneveld, J. Janssen, M.J. Kersten, J.H.F. Falkenburg, H. Sinnige, M. Schipperus, A. Schattenberg, M. van Marwijk Kooy, W.M. Smit, I. Chu, P. Valk, G.J. Ossenkoppele, J. Cornelissen. High dose Imatinib vers High dose Imatinib with Intermediate dose Cytarabine in ppatients with first chronic phase Chronic Myeloid Leukemia: a phase III trial of the dutch HOVON study group. Annals of Haematology 2013; 92(8):1049-56

 

N. Thielen, B. van der Holt, J.J. Cornelissen, G.E. Verhoef, T. Gussinklo, B.J. Biemond, S.M. Daenen, W. Deenik, R. van Marwijk Kooy, E. Petersen, W.M. Smit, P.J. Valk, G.J. Ossenkoppele, J.J. Janssen.

Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).

Eur J Cancer. 2013;49(15):3242-6.

 

E. Rombout-Sestrienkova, N. de Jonge, K. Martinakova, C. Klöpping, K.P. van Galen, A. Vink, E.M. Wajon, W.M. Smit, C. van Bree, Koek GH. End-stage cardiomyopathy because of hereditary hemochromatosis successfully treated with erythrocytapheresis in combination with left ventricular assist device support. Circ Heart Fail. 2014 May;7(3):541-3

 

H.H. Helgason, S.L. Koolen, E. van Werkhoven, M.M. Malingre, C.M. Kruijtzer, A.D. Huitema, M.E. Schot ME, W.M. Smit, J.H. Beijnen, J.H. Schellens. Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer. Curr Clin Pharmacol. 2014;9(2):139-47.

 

R. van der Noll, W.M. Smit, A.N. Wymenga, D.S. Boss, M. Grob, A.D. Huitema, H. Rosing, M.M. Tibben, M. Keessen, H. Rehorst, J.H. Beijnen, J.H. Schellens JH. Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. Invest New Drugs. 2015;33(6):1197-205

 

A. Boekhout, J. Gietema, B. Milojkovic Kerklaan, E. van Werkhoven, R. Altena , A.H. Honkoop , M. Los , W.M. Smit, P. Nieboer, C. Smorenburg, C. Mandigers, A. van de Wouw, L. Kessels, A van de Velden, P. Ottevanger, T. Smilde, J. de Boer , D.J. van Veldhuisen, I. Kema , E.E. de Vries, J.H. Schellens.  Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxicity in early breast cancer patients: a randomized, double-blind, placebo-controlled trial. JAMA Oncology 2016 (8) 1030-1037 

 

 

 

 

 

 

 

 

Lidmaatschappen

  • Nederlandse Internisten Vereniging
  • Nederlandse Vereniging voor Hematologie
  • Nederlandse Vereniging voor Medische Oncologie
  • European Hematology Association

Begin met typen om te zoeken..

Zoeken
Exact matches only
Search in title
Search in content
Search in excerpt
Filter by Custom Post Type
Pagina